(2-溴-3-(三氟甲基)苯基)甲胺盐酸盐 | 1214339-18-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (2-溴-3-(三氟甲基)苯基)甲胺盐酸盐
• 英文名称: (2-bromo-3-(trifluoromethyl)phenyl)methanamine hydrochloride
• 英文别名: 2-bromo-3-(trifluoromethyl)benzylamine hydrochloride；(2-Bromo-3-(trifluoromethyl)phenyl)methanamine hydrochloride；[2-bromo-3-(trifluoromethyl)phenyl]methanamine;hydrochloride
• CAS: 1214339-18-0
• 化学式: C₈H₇BrF₃N*ClH
• 分子量: 290.51
• InChiKey: MVJLSFCSZHEUOB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.35
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2-溴-3-(三氟甲基)苯基)甲胺盐酸盐 、 L-焦谷氨酸 在 2-乙氧基-1-乙氧碳酰基-1,2-二氢喹啉 作用下， 以 二氯甲烷 为溶剂， 反应 15.17h， 生成 (S)-N-(3-bromo-4-(trifluoromethyl)benzyl)-5-oxopyrrolidine-2-carboxamide
  参考文献：
  名称：

  Synthesis and in vitro biological evaluation of new P2X7R radioligands [11C]halo-GSK1482160 analogs

  摘要：

  The reference standards halo-GSK1482160 (F-, Br-, and I-) and their corresponding precursors desmethyl-halo-GSK1482160 (F-, Br-, and I-) were synthesized from (S)-1-methyl-5-oxopyrrolidine-2-carboxylic acid or (S)-5-oxopyrrolidine-2-carboxylic acid and 2-halo-3-(trifluoromethyl)benzylamine (F-, Br-, and I-) in one step with 45-93% yields. The target tracers [C-11]halo-GSK1482160 (F-, Br-, and I-) were prepared from desmethyl-halo-GSK1482160 (F-, Br-, and I-) with [C-11]CH3OTf under basic conditions (NaOH-Na2CO3, solid, w/w 1:2) through N-[C-11]methylation and isolated by HPLC combined with SPE in 40-50% decay corrected radiochemical yield. The radiochemical purity was > 99%, and the molar activity (A(M)) at end of bombardment (EOB) was 370-740 GBq/mu mol. The potency of halo-GSK1482160 (F-, Br-, and I-) in comparison with GSK1482160 (Cl-) was determined by a radioligand competitive binding assay using [C-11]GSK1482160, and the binding affinity K-i values for halo-GSK1482160 (F-, Br-, and I-) and GSK1482160 (Cl-) are 54.2, 2.5, 1.9 and 3.1 nM, respectively.

  DOI：

  10.1016/j.bmcl.2019.04.018

文献信息

• [EN] PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] MACROCYCLES PEPTIDIQUES ET LEUR UTILISATION DANS LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018189063A1

  公开（公告）日：2018-10-18

  The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8,R 8', R9, R9', X1, X2, X3, X4, X5, X6, X7, X8, X9 and X10 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.

  本发明提供了式（I）的化合物，其中R1，R2，R3，R4，R5，R6，R7，R8，R8'，R9，R9'，X1，X2，X3，X4，X5，X6，X7，X8，X9和X10如本文所述，以及其药学上可接受的盐。此外，本发明涉及式（I）化合物的制造，包含它们的制药组合物以及它们作为药物治疗Acinetobacter baumannii引起的疾病和感染的用途。
• PEPTIDE MACROCYCLES AND USE THEREOF IN THE TREATMENT OF BACTERIAL INFECTIONS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3388445A1

  公开（公告）日：2018-10-17

  The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R8', R9, R9', X1, X2, X3, X4, X5, X6, X7, X8, X9 and X10 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baumannii.

  本发明提供了式 (I) 的化合物 其中 R1、R2、R3、R4、R5、R6、R7、R8、R8'、R9、R9'、X1、X2、X3、X4、X5、X6、X7、X8、X9 和 X10 如本文所述，以及其药学上可接受的盐。此外，本发明还涉及式（I）化合物的制造、包含它们的药物组合物以及它们作为治疗鲍曼不动杆菌引起的疾病和感染的药物的用途。
• Peptide macrocycles and use thereof in the treatment of bacterial infections
  申请人：Hoffmann-La Roche Inc.

  公开号：US11091514B2

  公开（公告）日：2021-08-17

  The present invention provides compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R8′, R9, R9′, X1, X2, X3, X4, X5, X6, X7, X8, X9 and X10 are as described herein, as well as pharmaceutically acceptable salts thereof. Further the present invention is concerned with the manufacture of the compounds of formula (I), pharmaceutical compositions comprising them and their use as medicaments for the treatment of diseases and infections caused by Acinetobacter baurnannii.

  本发明提供了式 (I) 的化合物 其中R1、R2、R3、R4、R5、R6、R7、R8、R8′、R9、R9′、X1、X2、X3、X4、X5、X6、X7、X8、X9和X10如本文所述，以及它们的药学上可接受的盐。此外，本发明还涉及式(Ⅰ)化合物的制造、包含它们的药物组合物以及它们作为治疗鲍曼不动杆菌引起的疾病和感染的药物的用途。
• Synthesis and in vitro biological evaluation of new P2X7R radioligands [11C]halo-GSK1482160 analogs
  作者：Mingzhang Gao、Min Wang、Jill A. Meyer、Paul R. Territo、Gary D. Hutchins、Hamideh Zarrinmayeh、Qi-Huang Zheng

  DOI：10.1016/j.bmcl.2019.04.018

  日期：2019.6

  The reference standards halo-GSK1482160 (F-, Br-, and I-) and their corresponding precursors desmethyl-halo-GSK1482160 (F-, Br-, and I-) were synthesized from (S)-1-methyl-5-oxopyrrolidine-2-carboxylic acid or (S)-5-oxopyrrolidine-2-carboxylic acid and 2-halo-3-(trifluoromethyl)benzylamine (F-, Br-, and I-) in one step with 45-93% yields. The target tracers [C-11]halo-GSK1482160 (F-, Br-, and I-) were prepared from desmethyl-halo-GSK1482160 (F-, Br-, and I-) with [C-11]CH3OTf under basic conditions (NaOH-Na2CO3, solid, w/w 1:2) through N-[C-11]methylation and isolated by HPLC combined with SPE in 40-50% decay corrected radiochemical yield. The radiochemical purity was > 99%, and the molar activity (A(M)) at end of bombardment (EOB) was 370-740 GBq/mu mol. The potency of halo-GSK1482160 (F-, Br-, and I-) in comparison with GSK1482160 (Cl-) was determined by a radioligand competitive binding assay using [C-11]GSK1482160, and the binding affinity K-i values for halo-GSK1482160 (F-, Br-, and I-) and GSK1482160 (Cl-) are 54.2, 2.5, 1.9 and 3.1 nM, respectively.